Inflammatory Bowel Diseases (IBD) affects greater than 1.5 million people in our country. Although there is no known cause or treatment besides suppression, there are many contributing factors that with conscious awareness can improve the outcome in patients with IBD.
I personally see a strong link between stress and chronic degenerative diseases such as these. I also see a strong correlation between identifying and eliminating food allergies while taking in nutrients to support gut health to be essential steps. There is one medication that is also of great assistance called Low Dose Naltrexone. Taken in very low dosages at night before bed, endorphins are enhanced which improves immune responses and reverses self attacking self to self protecting self.
If you would like to be tested for food allergies, supported with nutrients specific for your body determined by a stool analysis you can schedule an appointment at our office at 480.970.0077.
If you would like to become more involved with supporting foundations that support IBD research, please consider the following event and visit ccaa.org.
Participants raise funds to help people suffering from Crohn’s disease and ulcerative colitis and are given all the necessary fundraising tools to do so, including a free customizable Web page for fundraising support and fundraising advice and assistance. Not only do participants help find cures, but there are incentives that can be earned at different fundraising levels.
Participating in Take Steps for Crohn’s & Colitis helps spread the word about Crohn’s disease and ulcerative colitis, two painful, unpredictable diseases that attack the digestive system. Crohn’s disease may attack anywhere in the digestive system, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, bleeding, fever and weight loss. Many patients require hospitalization and surgery. These illnesses can cause severe complications, including colon cancer in patients with long-term disease.